ARCHIVES

Ohio State Becomes 18th Comprehensive Center; UCLA Needs Only To Overcome “Minor” Problems

This article is from The Cancer Letter archive.

Vol. 02 No. 16 | April 16, 1976

Download PDF Visit The Full Archive

Related Articles

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

April 1, 2005

Soybean Studies, Computing Support Recompetition Ok’d

November 9, 1990

Agency Expands Gleevec Label To Include Rare GIST Subset

February 24, 2012

Vogel To Succeed Yates As VP for Research At American Cancer Society.

October 17, 2008

NCI SBIR Offers $10 million in 10 Awards

February 18, 2011

Amgen Takes Its Case for Aranesp To Lawmakers, Patients, Physicians

January 31, 2003